CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Illumina Inc - ILMN CFD

212.57
0.86%
0.40
Low: 210
High: 214.65
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.40
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Illumina Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 210.75
Open* 212.83
1-Year Change* -38.39%
Day's Range* 210 - 214.65
52 wk Range 173.45-428.00
Average Volume (10 days) 1.07M
Average Volume (3 months) 34.83M
Market Cap 34.95B
P/E Ratio -100.00K
Shares Outstanding 157.30M
Revenue 4.70B
EPS -26.46
Dividend (Yield %) N/A
Beta 1.15
Next Earnings Date Feb 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 25, 2023 210.75 2.76 1.33% 207.99 211.78 204.96
Jan 24, 2023 215.07 0.92 0.43% 214.15 217.89 212.09
Jan 23, 2023 216.12 12.49 6.13% 203.63 216.55 202.39
Jan 20, 2023 204.12 7.97 4.06% 196.15 204.69 193.87
Jan 19, 2023 196.19 -7.13 -3.51% 203.32 205.72 195.96
Jan 18, 2023 205.62 -1.94 -0.93% 207.56 212.03 203.70
Jan 17, 2023 206.23 5.70 2.84% 200.53 206.45 196.95
Jan 13, 2023 200.81 10.86 5.72% 189.95 201.53 189.71
Jan 12, 2023 193.65 -7.04 -3.51% 200.69 202.53 189.27
Jan 11, 2023 203.81 6.79 3.45% 197.02 204.44 193.97
Jan 10, 2023 194.39 9.69 5.25% 184.70 199.41 180.82
Jan 9, 2023 207.21 2.84 1.39% 204.37 210.67 203.57
Jan 6, 2023 201.61 -1.66 -0.82% 203.27 203.30 189.81
Jan 5, 2023 201.07 3.65 1.85% 197.42 203.71 195.57
Jan 4, 2023 202.50 -3.49 -1.69% 205.99 207.75 200.77
Jan 3, 2023 200.65 -1.81 -0.89% 202.46 205.92 196.54
Dec 30, 2022 201.92 4.54 2.30% 197.38 202.27 196.27
Dec 29, 2022 201.45 9.96 5.20% 191.49 205.15 189.55
Dec 28, 2022 190.63 2.36 1.25% 188.27 191.97 186.12
Dec 27, 2022 188.59 -0.36 -0.19% 188.95 190.24 185.15

Illumina Inc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 2398.37 2752 3333 3543 3239 4526
Revenue 2398.37 2752 3333 3543 3239 4526
Cost of Revenue, Total 731.925 908 1033 1076 1036 1372
Gross Profit 1666.45 1844 2300 2467 2203 3154
Total Operating Expense 1811.34 2146 2450 2504 2659 4649
Selling/General/Admin. Expenses, Total 583.005 674 794 835 941 2092
Research & Development 504.415 541 623 647 682 1185
Unusual Expense (Income) -8.004 23 0 -54
Operating Income 587.032 606 883 1039 580 -123
Interest Income (Expense), Net Non-Operating -23.382 435 8 75 237 919
Other, Net -2.472 2 3 4 39 88
Net Income Before Taxes 561.178 1043 894 1118 856 884
Net Income After Taxes 428.09 828 793 990 656 762
Minority Interest 34.559 48 44 12 0
Net Income Before Extra. Items 462.649 876 837 1002 656 762
Net Income 462.649 726 826 1002 656 762
Income Available to Common Excl. Extra. Items 462.649 876 837 1002 656 762
Income Available to Common Incl. Extra. Items 462.649 726 826 1002 656 762
Diluted Net Income 462.649 726 826 1002 656 762
Diluted Weighted Average Shares 148.04 148 149 149 148 151
Diluted EPS Excluding Extraordinary Items 3.12516 5.91892 5.61745 6.72483 4.43243 5.04636
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS 3.08392 6.04229 5.61745 6.40391 4.43243 5.04636
Total Extraordinary Items -150 -11
Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022
Total revenue 1093 1126 1108 1199 1223
Revenue 1093 1126 1108 1199 1223
Cost of Revenue, Total 329 324 338 382 408
Gross Profit 764 802 770 817 815
Total Operating Expense 900 939 1653 1158 1039
Selling/General/Admin. Expenses, Total 374 413 879 426 308
Research & Development 197 202 436 350 323
Operating Income 193 187 -545 41 184
Interest Income (Expense), Net Non-Operating -64 -12 931 64 -50
Other, Net 40 32 34 -19 6
Net Income Before Taxes 169 207 420 86 140
Net Income After Taxes 147 185 317 112 86
Net Income Before Extra. Items 147 185 317 112 86
Net Income 147 185 317 112 86
Income Available to Common Excl. Extra. Items 147 185 317 112 86
Income Available to Common Incl. Extra. Items 147 185 317 112 86
Diluted Net Income 147 185 317 112 86
Diluted Weighted Average Shares 147 147 153 157 159
Diluted EPS Excluding Extraordinary Items 1 1.2585 2.0719 0.71338 0.54088
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 1 1.2585 2.0719 0.71338 0.54088
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 2318.09 2980 4490 4451 4483 2713
Cash and Short Term Investments 1558.72 2145 3512 3414 3472 1339
Cash & Equivalents 734.516 1225 1144 2042 1810 1232
Short Term Investments 824.208 920 2368 1372 1662 107
Total Receivables, Net 381.316 411 514 573 487 648
Accounts Receivable - Trade, Net 380.93 411 514 573 487 648
Total Inventory 300.17 333 386 359 372 431
Prepaid Expenses 77.881 91 78 105 152 295
Total Assets 4280.6 5257 6959 7316 7585 15217
Property/Plant/Equipment, Total - Net 713.334 931 1075 1444 1454 1696
Property/Plant/Equipment, Total - Gross 1040.15 1347 1596 2012 2132 2492
Accumulated Depreciation, Total -326.813 -416 -521 -568 -678 -796
Goodwill, Net 775.995 771 831 824 897 7113
Intangibles, Net 242.652 175 185 145 142 3250
Other Long Term Assets, Total 230.528 400 378 452 609 445
Total Current Liabilities 704.665 746 1804 665 1244 1093
Accounts Payable 137.93 160 184 149 192 332
Accrued Expenses 392.296 376 256 263 287 429
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.25 10 1107 0 511 0
Other Current Liabilities, Total 173.189 200 257 253 254 332
Total Liabilities 2083.37 2508 3201 2703 2891 4477
Total Long Term Debt 1047.81 1182 890 1141 673 1695
Long Term Debt 1047.81 1182 890 1141 673 1695
Minority Interest 116.946 220 148 0
Other Liabilities, Total 213.955 360 359 897 974 1689
Total Equity 2197.23 2749 3758 4613 4694 10740
Common Stock 1.887 2 2 2 2 2
Additional Paid-In Capital 2733.39 2833 3290 3560 3815 8938
Retained Earnings (Accumulated Deficit) 1485.41 2256 3083 4067 4723 5485
Treasury Stock - Common -2022.43 -2341 -2616 -3021 -3848 -3702
Unrealized Gain (Loss) -2.326 -2 -2 4 1
Other Equity, Total 1.289 1 1 1 1 17
Total Liabilities & Shareholders’ Equity 4280.6 5257 6959 7316 7585 15217
Total Common Shares Outstanding 146.196 147 147 147 146 157
Preferred Stock - Non Redeemable, Net 0 0 0
Apr 2021 Jul 2021 Oct 2021 Jan 2022 Apr 2022
Total Current Assets 5642 5310 2451 2713 2755
Cash and Short Term Investments 4630 4286 1265 1339 1416
Cash & Equivalents 4433 4196 1080 1232 1351
Short Term Investments 197 90 185 107 65
Total Receivables, Net 517 540 604 648 630
Accounts Receivable - Trade, Net 517 540 604 648 630
Total Inventory 364 380 401 431 465
Prepaid Expenses 131 104 181 295 244
Total Assets 8755 8675 15063 15217 15274
Property/Plant/Equipment, Total - Net 1444 1481 1685 1696 1740
Goodwill, Net 897 966 7098 7113 7113
Intangibles, Net 134 162 3351 3250 3209
Other Long Term Assets, Total 638 756 478 445 233
Total Current Liabilities 1268 874 914 1093 1490
Accounts Payable 178 200 248 332 291
Accrued Expenses 298 365 391 429 377
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 488 0 0 0 499
Other Current Liabilities, Total 304 309 275 332 323
Total Liabilities 3833 3495 4470 4477 4379
Total Long Term Debt 1672 1679 1687 1695 1241
Long Term Debt 1672 1679 1687 1695 1241
Other Liabilities, Total 893 942 1869 1689 1648
Total Equity 4922 5180 10593 10740 10895
Common Stock 2 2 2 2 2
Additional Paid-In Capital 3914 3993 8849 8938 8957
Retained Earnings (Accumulated Deficit) 4870 5055 5372 5485 5632
Treasury Stock - Common -3872 -3878 -3643 -3702 -3714
Other Equity, Total 8 8 13 17 18
Total Liabilities & Shareholders’ Equity 8755 8675 15063 15217 15274
Total Common Shares Outstanding 146 146 157 157 157
Preferred Stock - Non Redeemable, Net 0
Long Term Investments 224
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 428 678 782 990 656 762
Cash From Operating Activities 779 875 1142 1051 1080 545
Cash From Operating Activities 90 110 140 151 156 176
Amortization 51 46 39 37 31 75
Deferred Taxes 94 81 -18 11 117 -76
Non-Cash Items 161 -235 217 56 47 -240
Cash Taxes Paid 60 149 99 164 119 233
Changes in Working Capital -45 195 -18 -194 73 -152
Cash From Investing Activities -515 -214 -1813 745 -554 -1069
Capital Expenditures -271 -312 -296 -209 -189 -208
Other Investing Cash Flow Items, Total -244 98 -1517 954 -365 -861
Cash From Financing Activities -296 -176 594 -897 -766 -51
Financing Cash Flow Items -33 8 18 -82 -91 -582
Issuance (Retirement) of Stock, Net -202 -180 -155 -265 -675 60
Issuance (Retirement) of Debt, Net -61 -4 731 -550 0 471
Foreign Exchange Effects -2 5 -4 -1 8 -3
Net Change in Cash -34 490 -81 898 -232 -578
Apr 2021 Jul 2021 Oct 2021 Jan 2022 Apr 2022
Net income/Starting Line 147 333 650 762 86
Cash From Operating Activities 282 535 263 545 172
Cash From Operating Activities 41 82 128 176 50
Amortization 7 15 34 75 41
Deferred Taxes -79 -156 -81 -76 -21
Non-Cash Items 104 167 -301 -240 81
Changes in Working Capital 62 94 -167 -152 -65
Cash From Investing Activities 1376 1379 -1069 -1069 -74
Capital Expenditures -42 -86 -138 -208 -61
Other Investing Cash Flow Items, Total 1418 1465 -931 -861 -13
Cash From Financing Activities 968 472 78 -51 21
Financing Cash Flow Items -24 -30 -452 -582 -12
Issuance (Retirement) of Stock, Net 31 31 59 60 33
Issuance (Retirement) of Debt, Net 961 471 471 471 0
Foreign Exchange Effects -3 0 -2 -3 0
Net Change in Cash 2623 2386 -730 -578 119
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Baillie Gifford & Co. Investment Advisor 10.6441 16743103 -2276998 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.1155 12765729 181808 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.0067 7875617 -70812 2022-09-30 LOW
Edgewood Management LLC Investment Advisor/Hedge Fund 4.7216 7427083 -741779 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.1761 6569010 87320 2022-09-30 LOW
Polen Capital Management, LLC Investment Advisor/Hedge Fund 2.8744 4521397 1731169 2022-09-30 LOW
Loomis, Sayles & Company, L.P. Investment Advisor/Hedge Fund 2.2875 3598290 -133808 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.1278 3347008 794245 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7894 2814723 62313 2022-09-30 LOW
Invesco Capital Management (QQQ Trust) Investment Advisor 1.334 2098412 -202259 2022-12-31 LOW
Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund 1.224 1925400 809753 2022-09-30 LOW
Walter Scott & Partners Ltd. Investment Advisor/Hedge Fund 1.1659 1833973 -210485 2022-09-30 LOW
Two Sigma Investments, LP Hedge Fund 1.1614 1826869 138559 2022-09-30 HIGH
Janus Henderson Investors Investment Advisor/Hedge Fund 1.1278 1773989 181237 2022-09-30 LOW
Nuveen LLC Pension Fund 1.0671 1678559 29844 2022-09-30 LOW
Veritas Asset Management LLP Investment Advisor/Hedge Fund 1.0116 1591247 27792 2022-09-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.001 1574624 671475 2022-09-30 LOW
Select Equity Group, L.P. Investment Advisor/Hedge Fund 0.9924 1561013 109439 2022-09-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.9053 1424051 1354 2022-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.8901 1400076 2726 2021-12-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Illumina Company profile

What is Illumina?

Illumina Inc (ILMN) is a San Diego-based U.S. company engaged in the development and marketing of genetic analysis solutions and life science services. Over the past decade it has become a global leader in genomics. Illumina offers a broad portfolio of instruments including NovaSeq Sequencing Systems,HiSeq Sequencing Systems, HiScan Array Scanner and others.

Illumina explains that its aim is “to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago”. The company says it delivers innovative, flexible, and scalable solutions to meet the needs of its customers.These customers include leading genome research centres and a variety of other academic, governmental, pharmaceutical and biotechnology institutions around the world.

In 2017 Forbes ranked Illumina no.18 in its annual list of the world’s most innovative companies. The company was also ranked no.34 in its league table of America's best midsize employers, and no.175 in Forbes’ list of growth champions. As of 6 April 2018, Illumina Inc had a market capitalisation of some $34.14 billion.

Who are the key people at Illumina?

Francis de Souza, who has been President & CEO of Illumina Inc since 2016, is responsible for directing all aspects of company strategy, planning and operations. Other key figures at the company include: Garret Hampton (Executive Vice President, Clinical Genomics); Omead Ostadan (Executive Vice President, Products & Operations); and Marc Stapley (Executive Vice President, Strategy & Corporate Development).

What is the modern history of Illumina?

The company was foundedin 1998 by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee. It acquired Spyder Instruments the following year, and completed its initial public offering in 2000. The acquisition of Solexa Inc followed in 2007, and Epicentre Biotechnologies was acquired in 2011. Roche made an unsolicited bid to buy Illumina for around $5.7 billion in 2012, but both this and a subsequent higher offer were rejected. In 2015, Illumina spun off the blood testing company Grail.

What are the latest developments at Illumina?

In its financial results for fiscal year 2017, Illumnia Inc reported revenue of $2.75 billion, a 15% increase from $2.40 billion in fiscal year 2016.GAAP net income attributable to Illumina stockholders was $726 million, or $4.92 per diluted share, against $463 million or $3.07 per diluted share in 2016.For fiscal year 2018, the company forecast 13-14% revenue growth, and GAAP earnings per diluted share attributable to Illumina stockholders of $4.14-$4.24.

Long-term investors in Illumina saw the value of their holdings increase significantly between 2013 and 2018. From $54 in January 2013, the Illumina share price climbed to $100 in December 2013, $150 in February 2014, and $200 in May 2015. The shares slipped in the second half of 2015, but by March 2018 the stock had recovered to a new high of $253. To find out how the shares are doing right now, follow Capital.com. Our ILMN chart puts all the information at your fingertips.

Where does Illumina operate?

Headquartered in San Diego, California,Illumina's regional subdivisions operate in the United States, Brazil, the United Kingdom, the Netherlands, Singapore, China, Japan and Australia.The company employs over 5,500 people.

Where is Illumina traded?

The company shares are traded on the NASDAQ stock exchange and are constituents of the S&P 500 index. Check out Capital.com for the latest ILMN chart. We’ll keep you up to date and in the picture.

Industry: Advanced Medical Equipment & Technology (NEC)

5200 Illumina Way
SAN DIEGO
CALIFORNIA 92122
US

Income Statement

People also watch

XRP/USD

0.40 Price
-4.660% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00446

Natural Gas

2.87 Price
-0.450% 1D Chg, %
Long position overnight fee 0.0855%
Short position overnight fee -0.1198%
Overnight fee time 22:00 (UTC)
Spread 0.005

ETH/USD

1,565.89 Price
-3.380% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 5.00

BTC/USD

22,693.05 Price
-3.990% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading